Eryseng Parvo (--) - Suspension for injection

Authorised

- Porcine parvovirus, strain NADL-2, Inactivated
- Erysipelothrix rhusiopathiae, strain R32E11, Inactivated

Product identification

Medicine name:
Eryseng Parvo (--) - Suspension for injection

Active substance:
Porcine parvovirus, strain NADL-2, Inactivated

Erysipelothrix rhusiopathiae, strain R32E11, Inactivated

Target species:
Pig

Route of administration:
Intramuscular use

Product details

Active substance and strength:
Porcine parvovirus, strain NADL-2, Inactivated

Presentation_strength:RP > 1.15 Reference:Ph Eur Index:0
Erysipelothrix rhusiopathiae, strain R32E11, Inactivated

Presentation_strength:ELISA > 3.34 IE50 % Reference:Ph Eur Index:1

Pharmaceutical form:

Suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Pig**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI09AL01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Bottle (PET), Package_size:1 bottle, Content:250 ml (125 doses)
Packaging:Bottle (PET), Package_size:1 bottle, Content:100 ml (50 doses)
Packaging:Bottle (PET), Package_size:1 bottle, Content:50 ml (25 doses)
Packaging:Bottle (PET), Package_size:1 bottle, Content:20 ml (10 doses)
Packaging:Vial (glass), Package_size:1 vial, Content:100 ml (50 doses)
Packaging:Vial (glass), Package_size:1 vial, Content:50 ml (25 doses)
Packaging:Vial (glass), Package_size:1 vial, Content:20 ml (10 doses)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Laboratorios Hipra, S.A.

Marketing authorisation date:
8/07/2014

Manufacturing sites for batch release:
Laboratorios Hipra S.A.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
8/07/2014

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 9/03/2026

Download

ema-puar-eryseng-parvo-v-2762-par-en.pdf